Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spyre TherapeuticsFRA:3920 29 5-Year Yield-on-Cost % is 0.00 as of Aug. 08, 2026. GuruFocus rates FRA:3920 with a GF Score™ of 29/100 and a GF Value™ of €1.98 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 150 Biotechnology companies, Spyre Therapeutics ranks worse than 666666% on this metric.
Spyre Therapeutics's yield on cost for the quarter that ended in Jun. 2026 was 0.00.
The historical rank and industry rank for Spyre Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:
FRA:3920's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.67 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Spyre Therapeutics 5-Year Yield-on-Cost % Related Terms
FRA:3920 vs CRNX, PTGX, PRAX: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Spyre Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spyre Therapeutics 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Spyre Therapeutics's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Spyre Therapeutics (FRA:3920) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 08, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Spyre Therapeutics and its competitors. According to the industry distribution chart, Spyre Therapeutics ranks #999999 out of 150 companies in the Biotechnology industry.
Is Spyre Therapeutics' 5-Year Yield-on-Cost % too high?
Spyre Therapeutics' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Spyre Therapeutics ranks #999999 out of 150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Spyre Therapeutics has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spyre Therapeutics' 5-Year Yield-on-Cost % compare to CRNX and PTGX?
According to the Biotechnology industry distribution chart, Spyre Therapeutics ranks #999999 out of 150 companies for 5-Year Yield-on-Cost %. This places Spyre Therapeutics in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.67, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Spyre Therapeutics and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spyre Therapeutics's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Spyre Therapeutics (FRA:3920) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.98, compared to a current price of €90.00 — trading 4445.5% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Spyre Therapeutics' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Spyre Therapeutics (FRA:3920), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spyre Therapeutics (FRA:3920) Overvalued in 2026?
Based on GuruFocus' analysis, Spyre Therapeutics stock appears to be overvalued.
The current stock price of €90.00 is trading 4445.5% above its estimated GF Value™ of €1.98.
GuruFocus considers Spyre Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:3920:
5-Year Yield-on-Cost %: 0.00
GF Value™: €1.98 vs. price of €90.00 (4445.5% above fair value)
No single metric tells the full story. See the FRA:3920 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
29GF Score
Get the complete analysis for FRA:3920
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3920 has been successfully added to your 
